Immunitybio (IBRX) closed at $8.81 on October 28, 2026, up 2.1% from the previous close, on volume of 6,640,713 shares (30-day average 14,306,184).
Data as of October 28, 2026.
28-Oct-2026
Market Chameleon (Wed, 21-Oct 4:14 AM ET)
Business Wire (Wed, 21-Oct 7:30 AM ET)
Business Wire (Fri, 16-Oct 11:49 AM ET)
Market Chameleon (Thu, 15-Oct 3:09 AM ET)
Business Wire (Wed, 14-Oct 4:18 PM ET)
ImmunityBio Taps Founder Patrick Soon-Shiong for an Oct. 16 Piper Sandler Oncology Fireside Chat
Market Chameleon (Fri, 9-Oct 7:37 AM ET)
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
Business Wire (Thu, 8-Oct 8:30 AM ET)
These High-Voltage Stocks Are Suddenly Impossible to Ignore
Globe Newswire (Fri, 2-Oct 11:44 AM ET)
HLS Therapeutics Announces Board of Directors Changes
PRNewswire (Thu, 1-Oct 7:00 AM ET)
Globe Newswire (Mon, 14-Sep 10:30 AM ET)
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Immunitybio trades on the NASDAQ stock market under the symbol IBRX.
As of October 28, 2026, IBRX stock price climbed to $8.81 with 6,640,713 million shares trading.
IBRX has a beta of 1.58, meaning it tends to be more sensitive to market movements. IBRX has a correlation of 0.03 to the broad based SPY ETF.
IBRX has a market cap of $9.34 billion. This is considered a Mid Cap stock.
Last quarter Immunitybio reported $51 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.00.
In the last 3 years, IBRX traded as high as $12.43 and as low as $1.83.
The top ETF exchange traded funds that IBRX belongs to (by Net Assets): VTI, XBI, VB, IWM, VBK.
IBRX has outperformed the market in the last year with a return of +231.2%, while the SPY ETF gained +13.8%. In the last 3 month period, IBRX beat the market returning +26.0%, while SPY returned +4.8%. However, in the most recent 2 weeks IBRX has underperformed the stock market by returning -10.1%, while SPY returned -0.7%.
IBRX support price is $8.13 and resistance is $9.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBRX shares will trade within this expected range on the day.
